- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 15686-71-2] Cephalexin
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B0200 |
| Brand: | MCE |
| CAS: | 15686-71-2 |
Overview
| MDL | MFCD00056877 |
|---|---|
| Molecular Weight | 347.39 |
| Molecular Formula | C16H17N3O4S |
| SMILES | O=C(C(N12)=C(C)CS[C@]2([H])[C@H](NC([C@H](N)C3=CC=CC=C3)=O)C1=O)O |
6 Publications Citing Use of MCE
Summary
Cephalexin (Cefalexin) is a potent, orally active semisynthetic cephalosporin antibiotic with a broad antibacterial spectrum. Cephalexin has antibacterial activity against a wide variety of gram-positive and gram-negative bacteria. Cephalexin targets penicillin-binding proteins (PBPs) to inhibit bacterial cell wall assembly. Cephalexin is used for the research of pneumonia, strep throat, and bacterial endocarditis, et al [1] [2] .
IC50 & Target
|
β-lactam
|
In Vitro
Cephalexin (10 μg/mL) disrupts polymer peptidoglycan (PG) biogenesis by inactivating enzymes called penicillin-binding proteins (PBPs)
[1]
.
Cephalexin inhibits a broad spectrum of grampositive and gram-negative organisms with MIC values of 2, 2, 2, 2, 4, 4.4 and 5.7 μg/mL for
Bacillus anthracis
,
Edwardsiella taFda
,
Vibrio cholera
,
Pasteurella multocida
,
Edwardsiella tarda
,
Alcaligenes sp
and
Proteus rettgeri
, respectively
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cephalexin (0-50 mg/kg; p.o.; for 3.5 hours) has antibacterial activity in male Swiss-Webster mice with infected bacterial [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Swiss-Webster mice with infected bacterial [2] |
| Dosage: | 0-50 mg/kg |
| Administration: | Oral administration; for 3.5 hours |
| Result: | Had antibacterial activity against Streptococcus pyogenes , Streptococcus pneumoniae , Staphylococcus aureus and several gram-negative species mice. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02123472 | Eli Lilly and Company|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V. |
Healthy Volunteers
|
May 2014 | Phase 1 |
| NCT01912651 | University of Michigan |
Facial Defect
|
July 2013 | Phase 4 |
| NCT01631617 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC) |
Eczema|Dermatitis|Skin Diseases, Genetic|Dermatitis, Atopic|Skin Diseases
|
September 18, 2012 | Phase 2 |
| NCT04876131 | Murdoch Childrens Research Institute|Royal Children´s Hospital |
Complicated Urinary Tract Infection|Infection|Pediatric Infectious Disease
|
May 30, 2022 | Phase 4 |
| NCT04834310 | University of California, Los Angeles |
Surgical Site Infection|Capsular Contracture Associated With Breast Implant|Antibiotic Resistant Infection|Antibiotic Side Effect
|
April 1, 2021 | Phase 4 |
| NCT01073553 | Bayer|Corporación Bonima S.A. de C.V. |
Anti-Infective Agents
|
October 2009 | Phase 1 |
| NCT03802552 | University of Colorado, Denver |
Osteomyelitis|Septic Arthritis|Pyomyositis
|
May 1, 2019 | Phase 1 |
| NCT04297592 | University of Iowa |
Infections Joint Prosthetic|Overweight or Obesity|MSSA Colonization|MRSA|Chronic Kidney Diseases|Diabetes|Autoimmune Diseases|Inflammatory Disease|Tobacco Use
|
June 11, 2020 | Phase 4 |
| NCT01029782 | Kelowna General Hospital|Canadian Society of Hospital Pharmacists|Capital Health, Canada|Interior Health Authority, Canada |
Cellulitis
|
May 2010 | Phase 2 |
| NCT01002911 | Population Health Research Institute |
Arrythmias
|
December 2009 | Phase 3 |
| NCT02569866 | Federal University of São Paulo|Universidade do Vale do Sapucai |
Surgical Site Infection
|
November 2014 | Phase 2 |
| NCT04580472 | Carilion Clinic |
Surgical Site Infection
|
October 1, 2020 | Phase 4 |
| NCT03736187 | Ain Shams University |
Surgical Site Infection
|
April 2019 | Not Applicable |
| NCT03187106 | The University of Texas Medical Branch, Galveston |
Surgical Site Infection
|
August 1, 2017 | Phase 1 |
| NCT01595529 | National Institute of Allergy and Infectious Diseases (NIAID) |
Urinary Tract Infection
|
May 18, 2012 | Phase 2 |
| NCT01155154 | State University of New York - Downstate Medical Center|Staten Island University Hospital|Kings County Hospital Center |
Simple Hand Lacerations
|
February 2010 | Not Applicable |
| NCT05020574 | University of California, San Francisco|The Plastic Surgery Foundation |
Breast Cancer|Breast Cancer Female|Genetic Predisposition to Disease
|
September 28, 2021 | Phase 2 |
| NCT04577846 | Aga Khan University|Liaquat National Hospital & Medical College|Dow University of Health Sciences |
Surgical Site Infection
|
November 1, 2020 | Phase 3 |
| NCT04553419 | University of British Columbia|The Hospital for Sick Children |
Cystic Fibrosis
|
July 27, 2020 | Phase 3 |
| NCT02490670 | Eli Lilly and Company|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V. |
Healthy
|
July 2015 | Phase 1 |
| NCT02145338 | Newcastle-upon-Tyne Hospitals NHS Trust|NHS Health Technology Assessment Programme|Newcastle University|Glasgow Caledonian University|University of Aberdeen|Cambridge University Hospitals NHS Foundation Trust|North Bristol NHS Trust|University of Southampton |
Urinary Tract Infections, Recurrent
|
September 2013 | Phase 4 |
| NCT00003824 | Southwest Oncology Group|National Cancer Institute (NCI) |
Bladder Cancer
|
April 1999 | Phase 3 |
| NCT04471246 | Ottawa Hospital Research Institute|The Ottawa Hospital Academic Medical Association|Canadian Association of Emergency Physicians |
Cellulitis
|
August 16, 2021 | Phase 4 |
| NCT00352612 | Aaron Chen|Thrasher Research Fund|Johns Hopkins University |
Staphylococcal Infection|Abscess|Staphylococcal Skin Infection|Folliculitis
|
September 2006 | Phase 4 |
| NCT00729937 | National Institute of Allergy and Infectious Diseases (NIAID) |
Staphylococcal Infection
|
April 2009 | Phase 2|Phase 3 |
| NCT02123446 | Eli Lilly and Company|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V. |
Healthy Volunteers
|
April 2014 | Phase 1 |
| NCT04916951 | University of Colorado, Denver |
Neonatal Infection
|
July 14, 2021 | Phase 1 |
| NCT00187759 | University of California, San Francisco |
Soft Tissue Infections
|
November 2004 | Not Applicable |
| NCT01507974 | HaEmek Medical Center, Israel |
Pregnancy Complications
|
January 16, 2012 | Not Applicable |
| NCT01073540 | Bayer|Corporación Bonima S.A. de C.V. |
Anti-Infective Agents
|
September 2009 | Phase 1 |
| NCT01767532 | GlaxoSmithKline |
Infections, Respiratory Tract
|
January 30, 2011 | Phase 1 |
| NCT01767584 | GlaxoSmithKline |
Infections, Respiratory Tract
|
April 6, 2009 | Phase 1 |
| NCT01194115 | University of Cincinnati |
Surgical Site Infection in Obese Women Undergoing C-section
|
September 2010 | Not Applicable |
| NCT05274672 | Baylor Research Institute|Albert Einstein Healthcare Network |
Benign Prostatic Hyperplasia|Urinary Tract Infections
|
March 1, 2022 | Phase 4 |
| NCT04538053 | Murdoch Childrens Research Institute |
Bone Infection|Septic Arthritis|Bone and Joint Infection|Osteomyelitis
|
June 1, 2021 | Phase 4 |
| NCT04194216 | Stanford University|Washington University School of Medicine|Vanderbilt University School of Medicine|University of Washington|Duke University|Harvard University|University of Kansas Medical Center|University of Cincinnati|Loma Linda University |
Nasal Obstruction|Nasal Surgical Procedures
|
May 20, 2020 | Phase 3 |
| NCT00234949 | Abbott |
Mild to Moderate Uncomplicated Skin and Skin Structure Infections
|
March 2005 | Phase 4 |
| NCT01400867 | Forest Laboratories|AstraZeneca |
Infections, Pediatrics
|
December 2011 | Phase 2|Phase 3 |
| NCT02014558 | Astellas Pharma Global Development, Inc.|Astellas Pharma Inc |
Acute Myeloid Leukemia
|
October 9, 2013 | Phase 1|Phase 2 |
| NCT00676130 | Brigham and Women´s Hospital |
Cellulitis
|
May 2007 | Not Applicable |
| NCT01767571 | GlaxoSmithKline |
Infections, Respiratory Tract
|
January 30, 2011 | Phase 1 |
| NCT02100826 | Eli Lilly and Company|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V. |
Healthy Volunteers
|
April 2014 | Phase 1 |
| NCT03148444 | Kaplan Medical Center |
Infection, Bacterial|Pacemaker Complication
|
June 1, 2017 | Phase 4 |
| NCT02911662 | Saint Joseph Mercy Health System |
Bacteriuria (Asymptomatic) in Pregnancy
|
September 2016 | Not Applicable |
| NCT02123459 | Eli Lilly and Company|Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V. |
Healthy Volunteers
|
May 2014 | Phase 1 |
| NCT01105208 | Bayer|Corporación Bonima S.A. de C.V. |
Anti-Infective Agents
|
March 2010 | Phase 1 |
| NCT03357419 | Rambam Health Care Campus |
Skin Lesion
|
March 2021 | Not Applicable |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 10 mg/mL ( 28.79 mM ; Need ultrasonic and warming)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8786 mL | 14.3930 mL | 28.7861 mL |
| 5 mM | 0.5757 mL | 2.8786 mL | 5.7572 mL |
| 10 mM | 0.2879 mL | 1.4393 mL | 2.8786 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (71.97 mM); Clear solution; Need ultrasonic and warming
References
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.